Author:
Li Danni,Lu Jiahao,Zhang Qiying,Zhou Yuzhu,Li Long,Zhu Hua,Li Tong
Abstract
AbstractDeregulation of NEK2(NIMA-related serine/threonine 2) confers chemotherapeutic resistance to apoptosis and is closely correlated with poor prognosis in hepatocellular carcinoma (HCC). Here, we find that nanoparticles are prepared through hemisynthesis from natural nitidine chloride (NC) with enhanced antitumor activity. Nitidine chloride nanoparticle (TPGS-FA/NC) treatment show good therapy effect in Li-7 hepatocellular carcinoma cells. Additionally, molecular docking technologies are aimed at NEK2 protein (PDB ID: 6SGD) to analyze the detailed binding interactions with the potent target. NC participates in interactions with Asp159 residue. These studies advance the understanding of the modification of nitidine chloride substituent and provide useful drug design information for liver cancer treatment.
Funder
Guangxi Natural Science Foundation
Guangxi Key Laboratory of Zhuang and Yao Ethnic Medicine
Collaborative Innovation Center of Zhuang and Yao EthnicMedicine
Publisher
Springer Science and Business Media LLC
Reference19 articles.
1. Chen W, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2014. Chin J Cancer Res. 2018;30(1):1–12.
2. Zhang S, Sun K, Zheng R, Zeng H, He J. Cancer incidence and mortality in China, 2015. J Natl Cancer Cent. 2020;1(1):2–11.
3. Rong SZ, Si WZ, Hong MZ, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2022;5(38):1–9.
4. Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
5. El-Serag HB, Siegel AB, Davila JA, Shaib YH, Cayton-Woody M, McBride R, et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population based study. J Hepatol. 2006;44:158–66.